Log in to search using one of your social media accounts:

This page shows you the latest items in this publication.

Amgen Reports First Quarter 2017 Financial Results
THOUSAND OAKS, Calif., April 26, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2017. Key results include: Total revenues decreased 1 percent versus the first quarter of 2016 to $5.5 billion. GAAP earnings per share (EPS) increased 12 percent to $2.79 driven by higher operating margins. GAAP operating income increased 8 percent to $2.6 billion and GAAP operating margin increased 4 percentage points to 49.8 percent. Non-GAAP EPS increased 9 percent to $3.15 driven by higher operating margins. Non-GAAP operating income increased 5 percent to $3.0 ...
Source: Amgen News Release - April 26, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Expanded Commercial Collaboration With Novartis For Erenumab In Migraine
Collaboration Designed to Maximize the Launch of First-in-Class Program and to More Effectively Reach People Living With Migraine THOUSAND OAKS, Calif., April 24, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced an expanded commercial collaboration with Novartis for erenumab, which is being investigated for the prevention of migraine. This expanded commercial collaboration builds on a global neuroscience collaboration in Alzheimer's disease and migraine established in 2015 between Novartis and Amgen. This expanded collaboration leverages Novartis' strong and established presence in neuroscience to more effect...
Source: Amgen News Release - April 24, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Webcast Of 2017 First Quarter Financial Results
THOUSAND OAKS, Calif., April 21, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Wednesday, April 26, 2017, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and...
Source: Amgen News Release - April 21, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Launches Neulasta ® (pegfilgrastim) Onpro® NARRATIVES
Online News Resource Highlights Importance of Patient and Care Team Dialogue THOUSAND OAKS, Calif., April 18, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of Neulasta® (pegfilgrastim) Onpro® NARRATIVES, an online media resource about the value of a cancer care team that provides comprehensive support for patients receiving strong chemotherapy. Intended to support conversations between cancer patients undergoing strong chemotherapy and their healthcare team about potential risk for infection due to a low white blood cell count, Neulasta Onpro NARRATIVES shares personal cancer stories as well as...
Source: Amgen News Release - April 18, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Submits Applications In The US And Europe To Expand Current Indication For XGEVA ® (denosumab) To Include Patients With Multiple Myeloma
XGEVA is Currently Indicated for the Prevention of Skeletal-Related Events Known as Bone Complications in Patients With Solid Tumors Applications Include Data From the Largest International Trial Conducted in Multiple Myeloma THOUSAND OAKS, Calif., April 4, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and an application for a variation to the marketing authorization to the European Medicines Agency (EMA) for XGEVA® (denosumab). The submissions to regulatory authorities seek to expand the...
Source: Amgen News Release - April 4, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY ™ (romosozumab)
THOUSAND OAKS, Calif. and BRUSSELS, April 1, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced results from the fourth year of a Phase 2 study showing the efficacy and safety of a second course of treatment with EVENITY™* (romosozumab), an investigational agent for postmenopausal women with osteoporosis. The results were presented in an oral session (OR08-1) at ENDO 2017, the Endocrine Society's Annual Meeting in Orlando, Fla. In the study, postmenopausal women with low bone mass (lumbar spine, total hip or femoral neck T score between -2.0 and -3.5) were initially randomized t...
Source: Amgen News Release - April 1, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting
Preclinical Results for Mcl-1 Inhibitor for Multiple Myeloma Accepted as Oral Presentation New Data on Bispecific T Cell Engagers (BiTE®) Immunotherapy Platform Preclinical Study Combining Different Immuno-Oncology Agents THOUSAND OAKS, Calif., March 31, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new preclinical data from its oncology portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting from April 1-5, 2017, in Washington, D.C. These data provide insights into the potential of Amgen's half-life optimized bispecific T cell engager (BiTE®) immunothera...
Source: Amgen News Release - March 31, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Grants Priority Review For Amgen's BLINCYTO ® (blinatumomab) Supplemental Biologics License Application
Application Includes Overall Survival Data From Phase 3 TOWER Study to Support Conversion From Accelerated Approval to Full Approval Acceptance Reinforces Significant Need for Innovative Treatment Options for Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia BLINCYTO is the First-and-Only Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy THOUSAND OAKS, Calif., March 29, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for BLINCYTO...
Source: Amgen News Release - March 29, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Journal Of Clinical Oncology Publishes Data On BLINCYTO ® (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
BLINCYTO is the Only Bispecific T Cell Engager (BiTE®) Immunotherapy Approved in the U.S. Complete Remission or Complete Remission With Partial Hematologic Recovery was Induced in More Than 35 Percent of Patients THOUSAND OAKS, Calif., March 29, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Journal of Clinical Oncology published results from the Phase 2, open-label ALCANTARA study evaluating the efficacy and safety of BLINCYTO® (blinatumomab) in patients with Philadelphia chromosome-positive (Ph+) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) who had failed at leas...
Source: Amgen News Release - March 29, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Awards Three Golden Tickets for LabCentral Residency
Innovative Start-Up Companies Receive One-Year Free Lab Space CAMBRIDGE, Mass., March 28, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and LabCentral announced that Cocoon Biotech, Torus Therapeutics, and Holobiome are the winners of Golden Ticket awards. Sponsored by Amgen, the Golden Ticket awards underwrite the cost of a lab bench for a scientist from each organization to reside in LabCentral's open lab for one year. LabCentral is an innovative, shared laboratory space designed as a launchpad for premier high impact life-sciences and biotech startups. Amgen entered into a multi-year platinum-level sponsorship with Lab...
Source: Amgen News Release - March 28, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

European Commission Approves AMGEVITA ™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases
First Biosimilar Adalimumab Approved in the European Union THOUSAND OAKS, Calif., March 23, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for AMGEVITA™ (biosimilar adalimumab1) in all available indications. AMGEVITA is authorized for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic evidence of AS; moderate-to-severe chronic plaque psoriasis; moderate-to-severe hi...
Source: Amgen News Release - March 23, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Analyses Of PCSK9 Inhibitor Prescription Rejection Rates Demonstrate Significant Access Barriers For Appropriate Patients
Results From Two Studies Show Approximately 80 Percent of Prescription Claims in the U.S. Are Initially Rejected No Major Differences in Patient Characteristics Between Those Approved and Those Denied Access to a PCSK9 Therapy by Payers Data Presented at ACC.17 Provide Further Insights Into Patient Barriers for Accessing PCSK9 Inhibitors THOUSAND OAKS, Calif., March 19, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from two studies that showed that for appropriate patients (on-label) in the U.S., the majority of prescription claims for PCSK9 inhibitors, such as Repatha® (evolocumab), were in...
Source: Amgen News Release - March 19, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Lowering LDL Levels With Repatha ® (Evolocumab) Did Not Adversely Affect Cognitive Function In Landmark Phase 3 Study
Repatha Cognitive Function Trial Evaluated Subset of Patients From Cardiovascular Outcomes Trial No Signal for Worsening Cognitive Function Observed Even in Patients Who Reached LDL Cholesterol Below 25 mg/dL Detailed Results From One of the Largest Randomized, Controlled Studies of Cognitive Function Presented at a Late-Breaking Clinical Trials Session at ACC.17 THOUSAND OAKS, Calif., March 18, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Repatha® (evolocumab) cognitive function trial (EBBINGHAUS) evaluating the impact on cognitive function in 1,974 patients enrolled in the ...
Source: Amgen News Release - March 18, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Landmark Outcomes Study Shows That Repatha ® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues
Repatha Significantly Reduces Risk of Hard Major Adverse Cardiovascular Events by 20 Percent Risks of Heart Attack, Stroke and Coronary Revascularization Were Nominally Reduced by 27 Percent, 21 Percent and 22 Percent, Respectively Patients in Study had History of Heart Attack, Stroke or Symptomatic Peripheral Arterial Disease and Were Treated With Optimized Statin Therapy Amgen to Offer Innovative Refund Contracts in the U.S. Detailed Results Simultaneously Published in the New England Journal of Medicine and Presented at the American College of Cardiology 66th Annual Scientific Session THOUSAND OAKS, Calif.,...
Source: Amgen News Release - March 17, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present At The Oppenheimer Global Health Care Conference
THOUSAND OAKS, Calif., March 16, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Oppenheimer Global Health Care Conference at 10:55 a.m. ET on Tuesday, March 21, 2017, in New York City. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, and David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the even...
Source: Amgen News Release - March 16, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Repatha ® (Evolocumab) Four-Year Open-Label Follow-Up Study Published In 'JAMA Cardiology'
Long-Term Study Identified No New Safety Concerns THOUSAND OAKS, Calif., March 14, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that four-year follow-up results from the Repatha® (evolocumab) OSLER-1 study, the longest PCSK9 inhibitor clinical trial to date, were published in JAMA Cardiology. Repatha, when added to standard of care (SOC), achieved median low-density lipoprotein cholesterol (LDL-C) reductions of 57 percent at four years, with no new safety concerns identified and no neutralizing antibodies observed with cumulative exposure.1 "For patients with cardiovascular disease, persistent LDL-C r...
Source: Amgen News Release - March 14, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Webcast Investor Meeting At Upcoming American College Of Cardiology Scientific Sessions
Late-Breaking Repatha® (Evolocumab) Presentations Will be Webcast Live at ACC.17 THOUSAND OAKS, Calif., March 14, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast investor meeting at the American College of Cardiology (ACC.17) Scientific Sessions on Friday, March 17, 2017, at noon ET. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team and clinical investigators, will participate at the investor meeting to discuss Amgen's cardiovascular program and data presented at ACC.17, including the Repatha® (evolocumab) cardiov...
Source: Amgen News Release - March 14, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Repatha ® (Evolocumab) Demonstrates Reduced Need For Apheresis In Patients With High LDL Cholesterol In Phase 3 Study
Study Meets Primary and All Secondary Endpoints THOUSAND OAKS, Calif., March 13, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive top-line results from a Phase 3 study evaluating Repatha® (evolocumab) in patients who were receiving apheresis to reduce low-density lipoprotein cholesterol (LDL-C). The study met its primary endpoint, demonstrating that treatment with Repatha significantly reduced the need for LDL-C apheresis in adult patients, as measured at the end of the randomized period. The study also met its secondary endpoints of percent change from baseline to week 4 in LDL-C, non-high-density...
Source: Amgen News Release - March 13, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces 2017 Second Quarter Dividend
THOUSAND OAKS, Calif., March 7, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a $1.15 per share dividend for the second quarter of 2017. The dividend will be paid on June 8, 2017, to all stockholders of record as of the close of business on May 17, 2017. About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand...
Source: Amgen News Release - March 7, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Highlights Landmark Repatha ® (Evolocumab) Cardiovascular Outcomes Study Amongst Data To Be Presented At ACC.17
Additional Presentations Include an Assessment of Repatha's Effect on Cognitive Function and Challenges Associated With Access to PCSK9 Inhibitor Therapy Late-Breaking Repatha Presentations Will be Webcast Live THOUSAND OAKS, Calif., March 6, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that detailed results of the Repatha® (evolocumab) cardiovascular outcomes trial will be presented, as well as new data from across the cardiovascular portfolio, at the American College of Cardiology 66th Annual Scientific Session (ACC.17) in Washington, D.C., March 17-19, 2017. Detailed results from the Repatha card...
Source: Amgen News Release - March 6, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Presents New Data From Phase 3 XGEVA ® (denosumab) Study In Multiple Myeloma Patients At The 16th International Myeloma Workshop
In this study, XGEVA® (denosumab) met the primary endpoint, demonstrating non-inferiority to zoledronic acid in delaying the time to first on-study skeletal-related event (SRE) in patients with multiple myeloma (HR=0.98, 95 percent CI: 0.85, 1.... (Source: Amgen News Release)
Source: Amgen News Release - March 3, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Presents Overall Survival Data From KYPROLIS ® (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop
Late-Breaking Presentation to Show Overall Survival Benefit of KYPROLIS Compared to Velcade® (Bortezomib) in Relapsed or Refractory Multiple Myeloma Patients First-and-Only Head-to-Head Study Comparing Proteasome Inhibitors to Demonstrate Statistically Significant Improved Overall Survival THOUSAND OAKS, Calif., March 3, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive results from a planned overall survival (OS) interim analysis of the Phase 3 head-to-head ENDEAVOR trial. The study met the key secondary endpoint of OS, demonstrating that patients with relapsed or refractory multiple myeloma treat...
Source: Amgen News Release - March 3, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present At The Cowen And Company 37th Annual Health Care Conference
THOUSAND OAKS, Calif., March 2, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Cowen and Company 37th Annual Health Care Conference at 11:20 a.m. ET on Wednesday, March 8, 2017, in Boston. Anthony C. Hooper, executive vice president of Global Commercial Operations at Amgen, and David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the...
Source: Amgen News Release - March 2, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

BLINCYTO ® (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy
BLINCYTO Almost Doubled Median Overall Survival in High-Risk Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared to Standard of Care Chemotherapy BLINCYTO is the First-and-Only Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy to Demonstrate Overall Survival Benefit in Patients With Philadelphia Chromosome-Negative Relapsed or Refractory Acute Lymphoblastic Leukemia Results Published in The New England Journal of Medicine THOUSAND OAKS, Calif., March 1, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the New England Journal of Medicine published results from the Phase 3 ...
Source: Amgen News Release - March 1, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present New KYPROLIS ® (Carfilzomib) And XGEVA® (Denosumab) Data At The 16th International Myeloma Workshop
Detailed Results From Phase 3 Head-to-Head ENDEAVOR Trial Show KYPROLIS Significantly Improved Overall Survival Compared to Velcade® (Bortezomib) in Relapsed or Refractory Multiple Myeloma Patients Late-Breaking Results From Largest International Trial Conducted in Multiple Myeloma Show XGEVA was Non-Inferior Versus Zoledronic Acid in Delaying Bone Complications THOUSAND OAKS, Calif., March 1, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from the KYPROLIS® (carfilzomib) and XGEVA® (denosumab) clinical development programs will be presented at the 16th International Myeloma Workshop (IMW...
Source: Amgen News Release - March 1, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Phase 3 Head-to-Head Trial Showed KYPROLIS ® (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade® (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients
First-and-Only Head-to-Head Study Comparing Proteasome Inhibitors to Demonstrate Statistically Significant Improved Overall Survival Detailed Results Will be Presented at the 16th International Myeloma Workshop (IMW) in New Delhi THOUSAND OAKS, Calif., Feb. 28, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive results from a planned overall survival (OS) interim analysis of the Phase 3 head-to-head ENDEAVOR trial. The study met the key secondary endpoint of OS, demonstrating that patients with relapsed or refractory multiple myeloma treated with KYPROLIS® (carfilzomib) and dexamethasone (Kd) lived ...
Source: Amgen News Release - February 28, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Repatha ® (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
Approval of the Automated Mini-Doser Marks First Hands-Free Administration Option for a PCSK9 Inhibitor in Europe THOUSAND OAKS, Calif., Feb. 21, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has adopted a decision to change the Repatha® (evolocumab) marketing authorization, approving a new single-dose delivery option. The new automated mini-doser (AMD) with a pre-filled cartridge is a hands-free device that provides 420 mg of Repatha in a single injection per administration. Repatha is the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in Europe wi...
Source: Amgen News Release - February 21, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Submits Supplemental Biologics License Application For BLINCYTO ® (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Application Includes Overall Survival Data From Phase 3 TOWER Study to Support Conversion From Accelerated Approval to Full Approval Additional Data Support Treatment of Patients With Philadelphia Chromosome-Positive Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia BLINCYTO is the First Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Antibody and First Immunotherapy to Demonstrate Overall Survival Benefit Versus Standard of Care Chemotherapy THOUSAND OAKS, Calif., Feb. 14, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a supplemental Biologics License A...
Source: Amgen News Release - February 14, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Approves Amgen's Parsabiv ™ (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis
Intravenous Administration Puts Delivery in Hands of Healthcare Provider THOUSAND OAKS, Calif., Feb. 7, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. Parsabiv is the first therapy approved for this condition in 12 years and the only calcimimetic that can be administered intravenously by the dialysis health care team three times a week at the end of the hemodialysis session. To view the ...
Source: Amgen News Release - February 7, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Appointment of Charles M. Holley Jr. to Board of Directors
THOUSAND OAKS, Calif., Feb. 3, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the appointment of Charles M. Holley Jr. to the Amgen Board of Directors. Mr. Holley will serve as a member of the Audit Committee and the Corporate Responsibility and Compliance Committee of the Board. Following the appointment of Mr. Holley, the Board will comprise 15 directors, 14 of whom are independent. "Charles Holley brings deep financial and organizational experience from one of the world's largest and most successful companies," said Robert A. Bradway, chairman and chief executive officer of Amgen. "We welcome Charles to Am...
Source: Amgen News Release - February 3, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Reports Fourth Quarter And Full Year 2016 Financial Results
THOUSAND OAKS, Calif., Feb. 2, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2016. Key results include: For the fourth quarter, total revenues increased 8 percent versus the fourth quarter of 2015 to $6.0 billion. Product sales grew 6 percent driven by Enbrel® (etanercept), Prolia® (denosumab), Repatha® (evolocumab) and KYPROLIS® (carfilzomib). For the full year, total revenues increased 6 percent to $23.0 billion, with 5 percent product sales growth. GAAP earnings per share (EPS) increased 9 percent in the fourth quarter to $2.59...
Source: Amgen News Release - February 2, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news